A phase IIb clinical trial for Galera Therapeutics’ GC4419 met its primary endpoint, demonstrating a significant (p=0.024), clinically meaningful and dose-dependent reduction in the duration of severe oral mucositis in patients with head and neck cancer receiving chemoradiation.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe